For many years, pharmaceutical companies have struggled to track products through the supply chain. This drawback has made it easy for counterfeiters to introduce fake drugs into the market.

The onset of the COVID-19 pandemic brought unprecedented disruption to drug development.

Paul Dickson, president of wholesale pharmaceutical distributor Morris & Dickson Co. LLC, describes efforts to allocate limited supplies of the antiviral drug remdesivir during the coronavirus pandemic.